Table 1 Baseline characteristics
Characteristic | No. of patients (%) |
|---|---|
Age, years | |
Median (range) | 53 (29–79) |
Sex | |
Female | 50 (100) |
Male | 0 (0) |
Race | |
White | 46 (92) |
Black | 1 (2) |
Asian | 1 (2) |
Other | 2 (4) |
Ethnicity | |
Hispanic or Latino | 12 (24) |
Non-Hispanic | 37 (74) |
Unknown | 1 (2) |
ECOG PS at baseline | |
0 | 32 (64) |
1 | 18 (36) |
Disease-free interval (from primary diagnosis to metastatic diagnosis) | |
De novo metastatic disease | 5 (10) |
≤ 2 years | 25 (50) |
> 2 years | 20 (40) |
Sites of disease at inclusion | |
CNS | 2 (4) |
Lung or pleural effusion | 13 (26) |
Liver | 5 (10) |
Bone | 8 (16) |
Breast or chest wall | 15 (30) |
Lymph nodes | 20 (40) |
Soft tissue | 2 (4) |
Other | 4 (8) |
Previous treatment | |
Adjuvant or neoadjuvant chemotherapy | 44 (88) |
Adjuvant or neoadjuvant anthracycline | 36 (72) |
Adjuvant or neoadjuvant taxane | 42 (84) |
Lines of chemotherapy for metastatic or recurrent disease | |
Median (range) | 1.5 (0–7) |
None | 7 (14) |
1 line | 18 (36) |
2 lines | 9 (18) |
3 or more lines | 16 (32) |
Prior metastatic chemotherapy | |
Anthracycline | 4 (8) |
Taxane | 14 (28) |
Platinum | 18 (36) |
Capecitabine | 23 (46) |
Eribulin | 8 (16) |
Other | 26 (52) |